Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POSLUMA vs ACTIVELLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PSMA-targeted radiotherapeutic agent; emits beta radiation causing DNA damage and cell death in PSMA-expressing cells.
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
Treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (m CRPC) who have received prior treatment with androgen receptor pathway inhibition and taxane-based chemotherapy.
Treatment of moderate to severe vasomotor symptoms associated with menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause,Prevention of postmenopausal osteoporosis
1.85 MBq (0.05 m Ci)/kg intravenously as a single injection, followed by PET imaging approximately 60 minutes post-injection.
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
Terminal elimination half-life: approximately 25–30 minutes for [68Ga]Ga-PSMA-11; rapid clearance from blood pool due to renal and hepatobiliary elimination.
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
Predominantly excreted renally; no significant hepatic metabolism.
Estradiol is metabolized primarily in the liver via CYP3A4 and other CYPs, as well as by 17β-hydroxysteroid dehydrogenase and sulfotransferases. Norethindrone acetate is metabolized in the liver, primarily via reduction and conjugation, with CYP3A4 involved in some oxidative metabolism.
Renal: 0% (not significantly eliminated via kidneys); Biliary/Fecal: predominantly eliminated via hepatobiliary system with fecal excretion of intact complex and metabolites, though precise % not established for human.
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Approximately 30–40% bound to plasma proteins (albumin minimally implicated; major binding to serum proteins not fully characterized).
Estradiol is ∼98% bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone is ∼95–97% bound to SHBG and albumin.
Central Vd ~ 0.2–0.3 L/kg (limited extravascular distribution; primarily confined to blood pool and highly perfused organs); high uptake in kidney, liver, spleen, salivary glands.
Estradiol has an apparent volume of distribution (Vd) of approximately 1.2 L/kg, indicating extensive distribution into tissues. Norethindrone has a Vd of approximately 3–5 L/kg, indicating wide distribution.
Intravenous: 100% (only route of administration).
Transdermal estradiol has a bioavailability of approximately 10% relative to oral administration due to avoidance of first-pass metabolism. Oral norethindrone acetate has a bioavailability of approximately 50–60%.
No formal dose adjustment recommendations; use with caution in severe renal impairment (e GFR <30 m L/min) due to potential increased radiation exposure.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated.
No specific dose adjustment guidelines; no data in Child-Pugh classes.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use caution and monitor; no specific dose adjustment established.
No approved pediatric indication; safety and efficacy not established in patients <18 years.
Not indicated for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment; consider age-related renal function decline and monitor for adverse effects.
Start with the lowest effective dose; monitor for thromboembolic events and cognitive effects. No specific dose adjustment required, but consider age-related renal and hepatic decline.
None.
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events, breast cancer, and probable dementia with estrogen plus progestin therapy. Actively monitor for these events.
Bone marrow suppression: Grade 3-4 thrombocytopenia, neutropenia, and anemia reported. Monitor blood counts.,Renal toxicity: Acute kidney injury and renal failure. Monitor renal function prior to and during therapy.,Hypersensitivity reactions: Monitor for signs and symptoms.,Radiation risks: Radiation exposure to patients, family, and healthcare providers; advise precautions.
Cardiovascular disorders: Increased risks of stroke, myocardial infarction, and venous thromboembolism (VTE).,Malignancy: Increased risk of breast cancer, endometrial cancer, and ovarian cancer.,Probable dementia: Increased risk in women aged 65 years or older.,Gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, and hereditary angioedema.,Retinal thrombosis: Discontinue if sudden vision loss occurs.,Laboratory tests: May alter thyroid function tests, coagulation tests, and glucose tolerance.
Hypersensitivity to the active substance or any excipients.
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Current or recent (within 1 year) VTE or ATE,Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency; factor V Leiden mutation),Active or past history of arterial thromboembolic disease (e.g., stroke, MI),Known liver impairment or disease,Known or suspected pregnancy,Hypersensitivity to any component of the product
No specific food interactions. Maintain adequate hydration before and after administration. No fasting required.
Grapefruit juice may increase estrogen levels by inhibiting CYP3A4; avoid excessive consumption. High-fat meals can increase absorption of oral estrogens; take consistently with or without food to maintain steady levels.
POSLUMA (flortaucipir F 18) is a radioactive diagnostic agent. No human studies on fetal harm. Animal studies not conducted. All radiopharmaceuticals carry potential risk to fetus; radiation dose may cause fetal harm, especially during organogenesis (first trimester). Use only if benefit outweighs risk. Second and third trimester: lower risk but still consider cumulative radiation exposure.
Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the second and third trimesters is contraindicated due to risk of fetal genital abnormalities and potential long-term neurodevelopmental effects. Avoid in pregnancy.
Not studied in breastfeeding women. Flortaucipir F 18 is excreted in human milk; M/P ratio unknown. Advise temporary cessation of breastfeeding for a period based on physical half-life (109.8 min) and residual activity; typical recommendation: interrupt nursing for at least 4 hours post-administration to reduce infant exposure.
Estradiol and norethindrone acetate are excreted into breast milk. Estradiol M/P ratio approximately 0.5; norethindrone M/P ratio approximately 0.4. May reduce milk production and alter composition. Use during breastfeeding is not recommended.
No specific dose adjustments recommended; however, minimize radiation dose using the lowest effective activity. Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may alter distribution, but no data for flortaucipir F 18. Use standard weight-based dosing.
Not applicable; contraindicated in pregnancy.
POSLUMA (Flotufolastat F 18) is a radioactive diagnostic agent for PSMA PET imaging in prostate cancer. Administer as an IV bolus (3-7 m Ci) followed by saline flush. Image 1-2 hours post-injection. No special patient preparation needed; assess for ability to lie still. Evaluate injection site for extravasation to avoid image artifacts. Report all adverse reactions to FDA Med Watch.
For patients with an intact uterus, estrogen must be combined with a progestogen (norethindrone acetate) to prevent endometrial hyperplasia. Initiate at the lowest effective dose for the shortest duration. Avoid in women with active thromboembolic disease, known or suspected breast cancer, or undiagnosed abnormal genital bleeding. Consider transdermal route if oral absorption is compromised or for migraine with aura.
This drug is a radioactive dye for PET scans to detect prostate cancer.,You will receive an injection into a vein, then wait about 1-2 hours before scanning.,Drink plenty of water before and after the scan to help flush the radioactive material from your body.,Tell your healthcare team if you are pregnant, breastfeeding, or have any allergies.,After the scan, avoid close contact with pregnant women and infants for several hours.,The radiation exposure is low and similar to other nuclear medicine tests.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, breast lumps, or symptoms of blood clots (e.g., leg pain, chest pain, sudden shortness of breath, vision changes) immediately.,Smoking increases the risk of cardiovascular side effects, especially in women over 35; avoid smoking while on this therapy.,This medication does not protect against sexually transmitted infections or HIV.,Regular medical check-ups, including breast exams and mammograms, are essential during therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POSLUMA vs ACTIVELLA, answered by our medical review team.
POSLUMA is a Radiopharmaceutical Diagnostic Agent that works by PSMA-targeted radiotherapeutic agent; emits beta radiation causing DNA damage and cell death in PSMA-expressing cells.. ACTIVELLA is a Estrogen/Progestin Combination that works by Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POSLUMA and ACTIVELLA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POSLUMA is: 1.85 MBq (0.05 m Ci)/kg intravenously as a single injection, followed by PET imaging approximately 60 minutes post-injection.. The standard adult dose of ACTIVELLA is: One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POSLUMA and ACTIVELLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POSLUMA is classified as Category C. POSLUMA (flortaucipir F 18) is a radioactive diagnostic agent. No human studies on fetal harm. Animal studies not conducted. All radiopharmaceuticals carry potential risk to fetus;. ACTIVELLA is classified as Category C. Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.